Edesa Biotech Shareholders Approve Key Proposals at AGM

Edesa Biotech ( (EDSA) ) has shared an announcement.

On May 28, 2025, Edesa Biotech held its Annual General and Special Meeting of Shareholders, where several key proposals were approved. Shareholders voted to amend the 2019 Equity Incentive Compensation Plan, increasing the shares available for issuance and the number of shares issuable as incentive stock options. Additionally, the election of directors and the appointment of MNP LLP as auditors for the fiscal year ending September 30, 2025, were confirmed. These decisions are expected to impact the company’s strategic direction and governance structure.

The most recent analyst rating on (EDSA) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on Edesa Biotech stock, see the EDSA Stock Forecast page.

Spark’s Take on EDSA Stock

According to Spark, TipRanks’ AI Analyst, EDSA is a Underperform.

Edesa Biotech exhibits significant financial challenges, reflected in zero revenue and persistent losses, severely impacting its overall score. Technical indicators show a stable market position, but poor valuation metrics further weigh down the stock’s attractiveness. The lack of revenue and cash flow sustainability poses significant risks.

To see Spark’s full report on EDSA stock, click here.

More about Edesa Biotech

Edesa Biotech, Inc. operates in the biotechnology industry, focusing on the development of innovative treatments for inflammatory and immune-related diseases.

Average Trading Volume: 20,619

Technical Sentiment Signal: Sell

Current Market Cap: $14.12M

See more data about EDSA stock on TipRanks’ Stock Analysis page.